Discovery of IRAK1/4/pan-FLT3 Kinase Inhibitors as Treatments for Acute Myeloid Leukemia

被引：1

作者：

Hoyt, Scott B. ^{[1
]}

Finocchio, Chris J. ^{[1
]}

Croll, Elizabeth ^{[1
]}

Tawa, Gregory J. ^{[1
]}

Li, Huixu ^{[2
]}

Ma, Li ^{[2
]}

Li, Kaikai ^{[2
]}

Liu, Li ^{[2
]}

Li, Ranran ^{[2
]}

Zhang, Xiaohu ^{[1
]}

Wilson, Kelli ^{[1
]}

Xu, Xin ^{[1
]}

Shah, Pranav ^{[1
]}

Williams, Jordan ^{[1
]}

Fang, Yuhong ^{[1
]}

Bolanos, Lyndsey C. ^{[3
]}

Gracia-Maldonado, Gabriel ^{[4
]}

Kolt, Amal ^{[4
]}

Robinson, Christina ^{[5
]}

Free, Jessica ^{[5
]}

Edmondson, Elijah F. ^{[5
]}

Difilippantonio, Simone ^{[5
]}

Jones, LaQuita M. ^{[6
]}

Culver-Cochran, Ashley E. ^{[3
]}

Rosenbaum, Jan S. ^{[4
]}

Starczynowski, Daniel T. ^{[3
]}

Thomas, Craig J. ^{[1
,7
]}

机构：

[1] Natl Ctr Adv Translat Sci, Rockville, MD 20850 USA

[2] WuXi AppTec Co Ltd, Tianjin 300457, Peoples R China

[3] Cincinnati Childrens Hosp Med Ctr, Div Expt Hematol, Cincinnati, OH 45229 USA

[4] Kurome Therapeut, Cincinnati, OH 45208 USA

[5] Frederick Natl Lab Canc Res, Frederick, MD 21702 USA

[6] Cincinnati Childrens Hosp Med Ctr, Div Oncol, Cincinnati, OH 45229 USA

[7] NCI, Bethesda, MD 20814 USA

来源：

ACS MEDICINAL CHEMISTRY LETTERS | 2024年 / 15卷 / 11期

基金：

美国国家卫生研究院;

关键词：

IRAK1; IRAK4; FLT3; kinase; AML; leukemia;

D O I：

10.1021/acsmedchemlett.4c00269

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

We report the discovery of an imidazopyridine series of IRAK1/4/pan-FLT3 kinase inhibitors. Optimization of this series has produced compound 31 which displays potent and selective inhibition of IRAK1, IRAK4, FLT3, and all mutant forms of FLT3, as well as good in vitro ADME and pharmacokinetic properties. In a mouse xenograft model of AML, 31 produces survival prolongation equal to that of Gilteritinib, the leading marketed FLT3 inhibitor currently used to treat AML.

引用

页码：1843 / 1851

页数：9

共 50 条

[41] Discovery of orally active indirubin-3′-oxime derivatives as potent type 1 FLT3 inhibitors for acute myeloid leukemia
Jeong, Pyeonghwa
Moon, Yeongyu
Lee, Je-Heon
Lee, So-Deok
Park, Jiyeon
Lee, Jungeun
Kim, Jiheon
Lee, Hyo Jeong
Kim, Na Yoon
Choi, Jungil
Heo, Jeong Doo
Shin, Ji Eun
Park, Hyun Woo
Kim, Yoon-Gyoon
Han, Sun-Young
Kim, Yong-Chul
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2020, 195
[42] Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens
Pratz, Keith
Levis, Mark
LEUKEMIA & LYMPHOMA, 2008, 49 (05) : 852 - 863
[43] Clinical Efficacies of FLT3 Inhibitors in Patients with Acute Myeloid Leukemia
Song, Moo-Kon
Park, Byeong-Bae
Uhm, Ji-Eun
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (20)
[44] Advancing treatment of acute myeloid leukemia: the future of FLT3 inhibitors
Elshoury, Amro
Przespolewski, Amanda
Baron, Jeffrey
Wang, Eunice S.
EXPERT REVIEW OF ANTICANCER THERAPY, 2019, 19 (03) : 273 - 286
[45] Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia
Weis, Taylor M.
Marini, Bernard L.
Bixby, Dale L.
Perissinotti, Anthony J.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2019, 141 : 125 - 138
[46] Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia
Short, Nicholas J.
Kantarjian, Hagop
Ravandi, Farhad
Daver, Naval
THERAPEUTIC ADVANCES IN HEMATOLOGY, 2019, 10
[47] Partnering with PARP inhibitors in acute myeloid leukemia with FLT3-ITD
Dellomo, Anna J.
Baer, Maria R.
Rassool, Feyruz V.
CANCER LETTERS, 2019, 454 : 171 - 178
[48] Mechanisms Underlying Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia
Eguchi, Motoki
Minami, Yosuke
Kuzume, Ayumi
Chi, SungGi
BIOMEDICINES, 2020, 8 (08)
[49] FLT3 Inhibitors in the Treatment of Acute Myeloid Leukemia The Start of an Era?
Pemmaraju, Naveen
Kantarjian, Hagop
Ravandi, Farhad
Cortes, Jorge
CANCER, 2011, 117 (15) : 3293 - 3304
[50] Incorporating FLT3 inhibitors in the frontline treatment of FLT3 mutant acute myeloid leukemia
Wang, Eunice S.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2019, 32 (02) : 154 - 162

← 1 2 3 4 5 →